Aditxt, Inc.

Listed Company

ADTXCIK 0001726711NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$3.2K

Net Income

$-43.10M

Total Assets

$16.52M

Equity

$5.61M

Shares Out

904.5K

Op. Cash Flow

$-25.69M

Business

Aditxt, Inc. develops and advances health innovations by identifying, securing, and building subsidiaries to commercialize diagnostic, therapeutic and population-health technologies. Its main offerings include the ADI immune-modulation therapeutic platform (ADI-100), the Pearsanta precision‑health biomarker and Mitomic® liquid‑biopsy programs, AditxtScore immune‑profiling assays, and antiviral/anti‑infective product development through Adivir. The company operates through distinct subsidiaries and supporting infrastructure for innovation, operations, commercialization, finance, and laboratory services. It distributes and advances programs via research and clinical partnerships, contract manufacturers and CROs, CLIA/CAP laboratory services, and U.S. and international regulatory and commercial channels.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Sales	3,195	133,985	645,176	933,715	105,034
Cost of goods sold	2,927	627,474	756,836	766,779	—
Gross profit (loss)	268	−493,489	−111,660	166,936	27,055
General and administrative expenses $0 and $33,071in stock-based compensation, respectively	16	16	19	16	22
Research and development $10,000 and $6,712,663 in stock-based compensation, respectively	3	11	7	7	5
Sales and marketing $473,311 and $0 in stock-based compensation, respectively	401,996	197,863	269,284	2	—
Total operating expenses	20	27	26	26	42
NET LOSS FROM OPERATIONS	−20	−28	−26	−25	−42
Interest expense	−681,156	−4	−4	—	—
Interest income	200,179	1,454	10,166	57,348	3,101
Amortization of debt discount	−2	−3	−2	−2	−2
Gain (loss) on note exchange agreement	—	−208,670	51,712	—	—
Change in fair value of derivative liability	14,515	414,501	—	—	—
Change in fair value of Evofem warrants	3	—	—	—	—
Impairment of Evofem F-1 Preferred Stock	−24	—	—	—	—
Bargain purchase gain from purchase of Evofem convertible notes	328,071	—	—	—	—
Impairment of fixed assets	−412,005	—	—	543,938	—
Total other expense	−23	−7	−6	−2	−4
Net loss before income taxes	−43	−35	−32	−28	−46
Income tax provision	—	—	—	—	—
NET LOSS	−43	−35	−32	−28	—
Deemed Dividends	−1	−6	−319,871	—	—
NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST	−1	−573,572	−9,608	—	—
NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES	−43	−40	−33	−28	−46
Net loss per share, basic (in Dollars per share)	−1,154	−22	−27,038	−597.12	−121.18
Net loss per share, diluted (in Dollars per share)	−1,154	−22	−27,038	−595.6	−121.18
Weighted average number of shares outstanding during the period, basic (in Shares)	37,355	2	1,209	46,369	381,811
Weighted average number of shares outstanding during the period, diluted (in Shares)	37,355	2	1,209	46,369	381,811
Change in valuation of Evofem note	1	—	—	—	—
TOTAL COMPREHENSIVE LOSS	−42	−35	—	—	—

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash	3	833,031	—	—	—
Accounts receivable, net	—	43,435	408,326	527,961	89,844
Inventory	5,774	11,245	745,502	950,093	—
Prepaid expenses	617,362	3,379	217,390	496,869	460,102
Subscription receivable	—	1	5	—	—
TOTAL CURRENT ASSETS	4	2	7	5	9
Fixed assets, net	880,241	2	2	2	—
Intangible assets, net	2,778	6,111	9,444	107,000	—
Deposits	61,586	87,672	106,410	355,366	379,250
Right of use asset	1	1	2	3	—
Convertible notes receivable, at fair value	4	—	—	—	—
Investment in Evofem	7	27	22	—	—
TOTAL ASSETS	17	32	45	11	17
Accounts payable and accrued expenses	8	13	9	2	2
Stock payable	—	2	—	—	—
Notes payable, related party	—	115,000	—	—	—
Notes payable, net of discount	2	6	16	—	—
Financing on fixed assets	—	147,823	147,823	409,983	—
Deferred rent	53,443	106,075	158,612	188,581	186,058
Operating lease liability, current	808,179	683,352	999,943	1	—
TOTAL CURRENT LIABILITIES	12	23	26	4	4
Operating lease liability, long term	342,904	436,354	1	2	—
Derivative liability	2	14,517	—	—	—
TOTAL LIABILITIES	13	24	29	6	6
COMMITMENTS AND CONTINGENCIES	—	—	—	—	—
TOTAL MEZZANINE EQUITY	—	7	—	—	—
Preferred stock, value	—	—	—	—	—
Common stock, $0.001 par value, 1,000,000,000 and 100,000,000 shares authorized, 411,500 and 194 shares issued and 411,499 and 193 shares outstanding, respectively	412	1	11	108	899
Treasury stock, 1 and 1 shares, respectively	−201,605	−201,605	−201,605	−201,605	−201,605
Additional paid-in capital	214	170	144	100	78
Accumulated deficit	−210	−168	−128	−95	−67
Accumulated other comprehensive income	1	—	—	—	—
TOTAL ADITXT, INC. STOCKHOLDERS EQUITY	6	2	16	5	10
NON-CONTROLLING INTEREST	−2	−583,180	−9,608	—	—
TOTAL STOCKHOLDERS EQUITY	4	1	16	5	10
TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS EQUITY	17	32	45	11	17

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	473,311	33,071	1	3	—
Stock-based compensation from asset purchase	10,000	7	—	—	—
Depreciation expense	269,271	613,918	435,027	428,977	369,236
Amortization of intangible assets	3,333	3,333	107,556	107,000	107,000
Amortization of debt discount - note receivable	−220,689	—	—	—	—
Loss on note exchange agreement	—	208,670	−51,712	—	—
Modification of warrants for debt issuance costs	—	376,901	—	—	—
New principal from extension of notes, net of debt discount	—	451,974	—	—	—
Disposal of fixed assets	—	3,000	—	6,976	—
Accounts receivable	43,435	364,891	119,635	−438,117	−312,460
Prepaid expenses	−613,983	214,011	279,479	−36,767	−306,954
Deposits	26,086	18,738	248,956	—	—
Inventory	5,471	734,257	204,591	−455,396	−494,697
Accounts payable and accrued expenses	−6	5	7	412,959	1
Settlement liability	—	667,000	—	—	—
Net cash used in operating activities	−26	−17	−19	−22	−22
Purchase of fixed assets	−13,743	—	−14,407	−367,079	—
Investment in convertible notes receivable and warrants	−2	—	—	—	—
Investment in Evofem F-1 preferred stock	—	−5	—	—	—
Net cash used in investing activities	−2	−5	−14,407	−241,918	−16
Proceeds from notes payable, related party	678,000	467,000	1	80,000	—
Proceeds from notes and convertible notes payable, net of offering costs	1	4	9	3	—
Repayments of note payable, related party	−793,000	−727,000	−687,523	−3	−315,790
Repayments of note payable	−7	−5	−3	−3	—
Common stock, preferred stock, and warrants issued for cash, net of issuance costs	44	21	11	—	—
Cash from subscription receivable	1	4	1,000	—	—
Proceeds from exercises of warrants	—	1	—	1	4
Redemptions of A-1 preferred stock	−308,000	—	—	—	—
Redemptions of C-1 preferred stock	−9	−3	—	—	—
Redemptions of D-1 preferred stock	—	−32	—	—	—
Net cash provided by financing activities	30	22	17	18	36
NET INCREASE IN CASH	2	735,929	−3	−5	—
Cash paid for income taxes	—	—	—	—	—
Cash paid for interest	2	1	3	753,038	—
Issuance of shares for the conversion of notes payable	—	500,000	—	—	—
Debt discount from shares issued as inducement for note payable	—	2	—	—	—
Warrant modification	—	6	319,871	37,677	—
Issuance of shares in asset purchase	—	266,448	10,000	—	—
Shares issued for settlement	—	2	—	80,000	—
Return of notes payable from Evofem merger agreement	—	11	—	—	—
Accrued interest rolled into notes payable	33,752	538,223	701,315	—	—
Settlement of liability for Series C-1 Convertible Preferred Stock	—	667,000	—	—	—
Subscription receivable	—	—	—	—	—
Exchange of warrants for Series C-1 convertible preferred stock	—	6	—	—	—
Derivative liability from conversion feature on preferred stock	—	429,018	—	—	—
ELOC payable	328,071	—	—	—	—
Series C-1 redemption payable	237,498	1	—	—	—
ELOC commitment fee stock payable	2	2	—	—	—
Loan in escrow	2	—	—	—	—
Reclassification of series A-1 preferred shares to liabilities	517,444	—	—	—	—
Write off of financed asset	147,823	—	—	—	—
Initial recognition of lease liability and right of use asset	800,359	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro